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MALIGNANT tumours of the male mammary gland are relatively rare. Men
accountonlyfor about 1 per cent ofbreast cancermaterials (Moss, 1965). Approxi-
mately 10 per cent of all tumours encountered in the male breast are malignant
(Jaaskelainen, 1951). The percentage of men in the Egyptian breast cancer
series reported by El-Gazayerli and Abdel-Aziz in 1963 was as high as 6.4, while
in a Finnish material it was 0.3 (Peltokallio et al., 1969). The difference has been
attributed to hyperoestrogenism caused by hepatic damage in bilharziasis.
Male mammary cancer is typically a disease of old men; the age of occurrence
is some 10 years higher than for women (Huggins and Taylor, 1955; Komurdjaev
and Rogoznaya 1964). The clinical picture bears a good resemblance to that seen
in women and the tumour tends to metastasise in the same sites and with the
same frequency. Because of the paucity of glandular tissue the tumour is
recognised more easily in men and spreads more rapidly into the surrounding
tissues such as the skin and muscles.
Malignant tumours of the male breast are so rare that it is difficult for an
individual physician or clinic to obtain experience of them. For this reason, we
collected the material from the whole country.
MATERIAL
The material consisted of all malignant tumours of the mammary gland
diagnosed and histologically verified in Finland in 1952-63 (Finnish Cancer
Register). The original case reports were all re-examined. A total of 51
malignant tumours of the mammary gland were diagnosed in Finland in these
years. They were distributed as follows according to the histologic picture:
carcinoma 42 cases, sarcoma 3 and malignant lymphoma 2 cases. In 4 cases the
malignancy ofthe tumour was not histologically certain. The proportion of male
patients in all cases ofbreast cancer in Finland during thisperiod was 0.54 per cent.
The annual morbidity was 0.19/100,000 men. Female breast cancer morbidity
during the same years averaged 32.9/100,000 per annum (Fig. 2). Three to seven
new cases oftumour ofthe male breast were established every year (Table I).
We shall consider here only the 42 histologically definite cases of male breast
cancer. The age distribution of the men is compared with the concomitant
female age distribution in Fig. 1. Both the median and mean age ofthe material
at the time of diagnosis was 66 years. The youngest patient was affected at the
age of 41 and the oldest at 91. As many as 7 patients were over 80 (Fig. 1).MALE BREAST TUMOURS IN FINLAND
TABLE I.-The Frequency of Male Brea8t Cancer in Finland in
the Year8 1953-63
Year of Number of cases
diagnosis Men Women
1953 . 4 610
1954 . 3 594
1955 . 3 610
1956 . 3 682
1957 . 5 746
1958 . 7 716
1959 7 672
1960 . 7 734
1961 . 4 696
1962 . 4 806
1963 . 4 818
Total . 51 7684
The average annual morbidity per 100,000
The population of Finland is 4* 5 million.
Women
inhabitants was 0 19 for men and 32 9 for women.
Men
100 50 0. 4 8 12 16 number of patients
FIG. 1.-Age distribution of the Finnish men with breast cancer in the years 1952-63 compared
with a material of Finnish women (Peltokallio et al., 1969).
Breast cancer was localised in our series with equal frequency on the right and
left side (20 cases each). Two patients had mammary cancer at different times
in both breasts.
The frequency ofthe commonest symptoms was as follows:
Symptom
Palpable tumour
Nipple discharge
Other symptoms
Per cent
82
28
20 . (nipple retraction,
general symptoms,
axillary metastasis, etc).
40 |^--J
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Most ofthe patients had themselves observed a tumour in the breast. Nipple
discharge was a frequent symptom, and it was usually bloody. The duration of
the symptoms varied from a week to 3 years, mean 12 months.
The tumour was still local at the time ofoperation in 47 per cent ofthe patients
(I-IH stage ofthe Columbia Clinical Classification); it was already more advanced
in 53 per cent (III-IV stage).
U 10 30 50 70 90 Y
FiG. 2.-The morbidity of breast cancer in different ages, both women and men. Numbers are
calculated per 100,000 men and women (logarithmic scale).
Two out of 3 patients had " radical mastectomy " or another operation
regarded as radical. They were also given radiotherapy. Seven patients received
radiotherapy alone and the remaining 7 patients had surgery alone. It was
regarded as radical in 4 cases. Because the material was too small and the
treatment selected was based on the patient's general condition and the size and
stage of the tumour, no conclusions can be drawn about the therapeutic results
obtained by the different methods.
As regards prognosis, too, we have confined ourselves to the histologically
verified cases of carcinoma (42 patients). They were followed up for 5-15 years.
It was possible to verify either the cause of death or the present status in all the
cases. The observed 5-year survival rate for the total material was 26 per cent
and the median survival time was 2 years 3 months. When the carcinoma was
local at the time of operation, 50 per cent of the patients were alive after 5 years
and their median survival time was 4 years 8 months. When the disease was far
advanced, the corresponding figures were 6 per cent and 1 year 9 months. The
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patients' prognosis is presented schematically in Fig. 3. It shows that the patients
may live a long time after successful therapy. One of our patients had had
unilateral mastectomy 20 years ago for carcinoma. He developed carcinoma in
the remaining breast 4 years ago, and this was also treated successfully. The
patient is still alive at 81. We divided our material into two groups according
to the median age (66 years) so that there were 21 patients in each group. The
cancer mortality rate was higher in the younger than in the older group in which
vascular and cardiac diseases constituted the greatest cause of death.
100
50 ..female
male
OL **
1 2 3 4 5 6 7 8 9y
FiG. 3.-The prognosis of breast cancer. The broken line for men means that only a part has
been followed for such a long time. The upper curve shows the prognosis for women in a
Finnish material (Peltokallio et al., 1969).
Cau8e of Death
Mammary cancer Other disease Survivors
Age, years Per cent Per cent Per cent
Under 66 . 44 . 26 . 30
Over 66 . 35 . 50 . 15
The median survival time for the younger patients was 2 years 2 months and
for the older 2 years 6 months. On the other hand, the observed 5-year survival
rate for the former was 30 and for the latter 22 per cent (Fig. 4). The relative
5-year survival rate (or the survival rate adjusted for normal life expectancy) for
the younger group was 34 and for the older 39 per cent. The relative 5-year
survival rate of the whole material was 34 per cent.
One of the 3 patients with sarcoma died 2 years 2 months after diagnosis of
the disease. The other 2 are still alive.
DISCUSSION
The incidence of both female and male mammary cancer is fairly small in
Finland. Male mortality in 1953-63 averaged 0.1/100,000 inhabitants, while
the comparable figure in e.g. the UnitedStateswas0g2 (Edelman, 1967). Morbidity
in Finland in these years averaged 0-19/100,000 men.
483PEKKA PELTOKALLIO AND TIMO V. KALIMA
5-YEAR SURVIVAL
I ~~~~~~~~~~~iT
58Y median age 75 y
100
5.0 5_0
O 1 2 3 4 5 6yearso 1 2 3 4 5 6
FiG. 4.-The material is divided into two equal parts according to the median age. The median
age of group I (under 66 years) is 58 years and in group II (over 66 years) 75 years. The
observed survival rates (continuous line) and the age adjusted or relative survival rates
(broken line) of both groups are presented.
Cancer of the male breast appears to be a disease of the elderly in particular.
Every seventh patient in our series was over 80, andthe mean as well as the median
age was 66 which is about 10 years higher than in the corresponding female cancer
material (Peltokallio et at., 1969).
Mammary cancer was bilateral in 2 of our cases (5 per cent). Treves and
Holleb (1955) reported bilateral mammary cancer in 2-7 per cent oftheir material,
and Moss in 1965 in 0-8 per cent.
Our material showed no evidence ofhereditary cancer of the male breast.
The role of trauma in the aetiology of cancer of the male mammary gland has
always been an interesting topic. Gilbert reported in 1933 preceding trauma
in as high a percentage as 29, Holleb and his co-workers (1968a) in 10 per cent.
Like many other authors (Somerville, 1952; Greening and Aichroth, 1965), we
were unable to confirm the role oftrauma in our series. It probably merely helps
the patient notice the abnormality in his mammary gland.
Gynaecomastia was present in only one of our cases. Its incidence was 19
per cent in one material (Gilbert, 1933). However, most workers have been
unable to establish a causal relationship between breast cancer and gynaecomastia
(Huggins and Taylor, 1955; Treves andHolleb, 1955; Greening and Aichroth 1965).
Hormone therapy has been blamed as a factor inducing breast cancer.
Lacassagne in 1932 produced mammary carcinoma experimentally in mice by
means of oestrogen. El-Gazayerli and Abdel-Aziz (1963) attributed the high
incidence of mammary carcinoma in Egyptian men, and particularly in consider-
ably younger men than elsewhere (mean age 41 years), to hyperoestrogenism
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arising from liver damage in bilharziasis. Bilateral mammary carcinoma following
oestrogen therapy was described by McClure and Higgins (1951). However,
Campbell and Cummins (1951) in their critical analysis of 12 corresponding
cases reported in the literature concluded that there were prostatic metastases
in the mammary gland rather than primary oestrogen-induced tumours.
Komurdjaev and Rogoznaya (1964) also observed a distinctly higher urinary
oestrogen level in males with mammary carcinoma than in healthy men. Holleb
et al. (1968a) were unable to corroborate in their material the hypothesis that
oestrogen therapy increases the incidence of carcinoma of the male breast.
Bearing in mind the great number of patients receiving hormone therapy for
carcinoma of the prostate and, on the other hand, the rarity of male carcinoma,
the aetiological role of oestrogen therapy can hardly be confirmed statistically
(Greening and Aichroth, 1965). There was not a single cases with prostatic
carcinoma in our own material which, after all, comprises every case in Finland for
a period of 11 years.
By far the commonest of the symptoms was a lump in the breast detected by
chance by the patient himself. The patients rarely sought medical advice for
other symptoms. Every fifth patient in ourownserieshadnippledischarge. Dis-
charge from the nipplein a manis so often suggestive of carcinoma that it requires
immediate and careful examination. It must be regarded as a sign of carcinoma
unless proved otherwise histologically (Holleb et al., 1968a). Abenigntumour can
also cause nipple discharge occasionally (Treves et al., 1956). A typical feature of
male carcinoma is that it is generally localised in the vicinity of the mammilla.
The tumour is usually adherent to the skin, mammilla (Somerville, 1952-73 per
cent) or the fascia of the pectoralis muscle (Somerville 1952-61-1 per cent;
Greening and Aichroth, 1965-68 per cent; Rissanen, 1968-45 per cent). The
men were late in seeking treatment for their mammary carcinoma. The symptoms
had persisted for an average of 12 months. Similar delay appears to occur
elsewhere (Treves and Holleb, 1955; Greening and Aichroth, 1965; Edelman,
1967). The main cause of the delay is probably the patient's ignorance of the
possibility of cancer of the male breast. Diagnosis is delayed because the lump
is generally regarded as benign until skin changes and nipple fixation occur.
Payson and Rosh (1949) established fixation to the skin in 44 per cent ofmen with
benign tumours. Hence, fixation to skin need not necessarily mean a malignant
tumour in a male patient, though it almost invariably does in women.
The traditional radical mastectomy must be regarded as the primary therapy
for carcinoma of the male breast. It is the treatment of choice for all patients
with favourable and border line lesions (Guthorn, 1951; Rubin, 1967; Holleb et al.,
1968b). Simple mastectomy has a poorer prognosis than radical mastectomy
(Moss, 1965). According to Huggins and Taylor (1955), so many local recurrences
are encountered after minor operations that they are not to be recommended.
Age does not affect the choice of therapy. The only contraindication is far-
advanced disease. In these cases, simple mastectomy is recommended, often for
hygienic reasons alone (Somerville, 1952). In order to achieve sufficiently radical
removal, skin grafting is necessary for men (Moss, 1965; Holleb et al., 1968b). A
local recurrence close to the scar is common, even in as many as 25 per cent
(Greening and Aichroth, 1965). Distant metastases mostly originate in the bones
and lungs (Rissanen, 1968) and may appear several years after the primary
operation (Greening and Aichroth, 1965). Radiotherapy and hormone therapy
485PEKKA PELTOKALLIO AND TIMO V. KALIMA
are ofpalliative value in less favourable cases. Rissanen (1968) believed that the
low local recurrence rate (7.5 per cent) in his series was due to the radiotherapy
administered to all the patients. Hormone therapy lengthens the patients'
life. Orchiectomy as initial therapy gives the best results. Bilateral adrenalec-
tomy is also beneficial in far advanced cases (Huggins and Taylor 1955; Moss,
1965; Rubin, 1967; Holleb et al., 1968b).
The prognosis for men with carcinoma of the breast in Finland was poorer
than the prognosis for women with mammary carcinoma. The observed 5-year
survival rate was 26 per cent in our material and the relative 5-year rate was 34
per cent. The corresponding female observed 5-year survival rate in the same
period was 51 per cent (Peltokallio et al., 1969). According to the Finnish Cancer
Register, the observed 5-year survival rate for women was 52 per cent and the
relative ratio 54 per cent (Hakama, 1964). When the carcinoma in men was
local and operated radically 50 per cent survived over 5 years.
A factor contributing to the poorer prognosis for men is that they came later
for treatment. The average duration of symptoms for women was 4 months, for
men 12 months. The disease was in a more favourable stage for treatment
(1-11 stages Columbia Clinical Classification) in 70 per cent of the women
(Peltokallio et al., 1969) and in only 47 per cent ofthe men. It is possible that the
paucity and inactivity ofglandular tissue also impair the prognosis.
The prognosis for carcinoma of the male breast seems to be poor everywhere
(Table II). The prognosis for men would hardly be poorer, however, ifthe disease
TABLE II.-The Prognosis of Male Brecast Cancer in Different Materials
Number Observed 5-year
Material of cases survival rate
Payson and Rosh, 1949 . . . 16 . 18 8
Guthorn, 1951 . . . . . 15 . 27-0
Somerville, 1952 . . . . . 19 . 27-4
Huggins and Taylor, 1955 . . . 75 . 8-0
Treves and Holleb, 1955 . . . . 146 . 29 0
Greening and Aichroth, 1965 . . . 28 . 36 0
Peltokallio and Kalima, 1969 . . . 42 . 26X0
were diagnosed inthem in the same stage as inthefemale cases (Treves etal., 1956).
Taking all the stages of the disease into consideration the prognosis for men is
more ominous than for women, but when axillary metastases are present the
survival time is the same and when distant metastases are found men live longer
on the average than women (Moss, 1965).
The age-adjusted survival rates for our material show that the risk of death
from mammary carcinoma is greater among the younger than the older patients.
Treves and his co-workers (1956) claimed that age is not of significance for the
prognosis; however, the course of the disease appears to be more favourable
in patients over 70 years of age.
SUMMARY
The incidence of both male and female breast carcinoma is lower in Finland
than in manyother countries. The average male annual morbidity rate in 1953-63
was 0-19/100,000. Men accounted for 0-54 per cent of all cases of mammary
carcinoma. The material analysed here consisted of all malignant tumours of
the male breast diagnosed and studied histologically in Finland in 1935-63.
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There were 51 patients in all. Carcinoma was verified in 42 of these cases.
Men appeared to develop the disease almost 10 years later than women. The
mean age of the patients was high, 66 years. Two patients had carcinoma in
both breasts. Judging by this material, heredity, trauma, gynaecomastia or
earlier hormonal therapy play no role in the genesis of carcinoma of the male
breast. Men came late for treatment because they could not imagine that they
could develop mammary carcinoma. The average delaywas 12 months, compared
with only 4 months for women. The disease had also spread further in men by
the time of diagnosis. The percentage of men operated on in a therapeutically
favourable phase was only 47, compared with 70 per cent of the women. Both
these factors contributed to making the male prognosis distinctly inferior to that
for a corresponding female breast cancer material. Of the total material, 26 per
cent ofthe men and 51 per cent ofthe women survived over5years. Therelative
5-year survival rate for men was 34 per cent and for women 54 per cent. The
Finnish man had a poorer prognosis than the Finnish woman even when the
carcinoma of the mammary gland was treated in an early stage. Classical
radical mastectomy is regarded as the therapy of choice also in carcinoma of the
male breast. Of the patients that it was possible to treat for cure, 50 per cent
were alive after 5 years. Younger patients appeared to have a slightly poorer
carcinoma prognosis than older ones who often die ofother diseases.
This investigation was aided by a grant from the President J. K. Paasikivi's
Foundation, Helsinki, Finland.
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